ProfileGDS5678 / 1423810_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 83% 82% 85% 83% 84% 84% 83% 84% 84% 83% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1060684
GSM967853U87-EV human glioblastoma xenograft - Control 26.142783
GSM967854U87-EV human glioblastoma xenograft - Control 36.1364983
GSM967855U87-EV human glioblastoma xenograft - Control 46.1213282
GSM967856U87-EV human glioblastoma xenograft - Control 56.3879185
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9096483
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0972184
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1290584
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0642183
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2515584
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1697584
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0870383
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1733484
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.133884